Latest Insider Transactions at Sanara Med Tech Inc. (SMTI)
This section provides a real-time view of insider transactions for Sanara Med Tech Inc. (SMTI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Sanara MedTech Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Sanara MedTech Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 05
2022
|
Zachary B. Fleming Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
265
-0.68%
|
$5,565
$21.45 P/Share
|
|
Jun 29
2022
|
Zachary B. Fleming Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
294
-0.75%
|
$6,174
$21.0 P/Share
|
|
Jun 28
2022
|
Zachary B. Fleming Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
69
-0.18%
|
$1,449
$21.0 P/Share
|
|
Jun 24
2022
|
Zachary B. Fleming Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
457
-1.15%
|
$9,597
$21.0 P/Share
|
|
Jun 17
2022
|
Shawn M. Bowman |
SELL
Open market or private sale
|
Direct |
1,000
-4.87%
|
$20,000
$20.02 P/Share
|
|
Mar 08
2022
|
Shawn M. Bowman |
BUY
Grant, award, or other acquisition
|
Direct |
2,284
+10.0%
|
-
|
|
Mar 08
2022
|
Zachary B. Fleming Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,831
+18.17%
|
-
|
|
Mar 08
2022
|
Rebecca E Mc Mahon President - R&D |
BUY
Grant, award, or other acquisition
|
Direct |
2,047
+21.7%
|
-
|
|
Mar 08
2022
|
Michael D. Mc Neil Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,547
+24.32%
|
-
|
|
Feb 09
2022
|
James W Stuckert Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,118
+0.43%
|
-
|
|
Feb 09
2022
|
Roszell Mack Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,125
+50.0%
|
-
|
|
Feb 09
2022
|
Robert Andrew De Sutter Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,331
+37.5%
|
-
|
|
Feb 09
2022
|
Sara N Ortwein Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,481
+37.8%
|
-
|
|
Feb 09
2022
|
Eric D Tanzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,337
+50.0%
|
-
|
|
Feb 09
2022
|
Ronald T Nixon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,937
+19.93%
|
-
|
|
Feb 09
2022
|
Ann Beal Salamone Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,021
+26.4%
|
-
|
|
Feb 09
2022
|
Kenneth E Thorpe Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,508
+27.63%
|
-
|
|
Jan 01
2022
|
Christopher A. Morrison President - Telehealth Svcs. |
BUY
Grant, award, or other acquisition
|
Direct |
7,135
+20.29%
|
-
|
|
Jan 01
2022
|
Zachary B. Fleming Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+24.43%
|
-
|
|
Dec 22
2021
|
Zachary B. Fleming Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,993
+16.02%
|
-
|
|
Dec 22
2021
|
Shawn M. Bowman |
BUY
Grant, award, or other acquisition
|
Direct |
3,195
+14.92%
|
-
|
|
Dec 22
2021
|
Michael D. Mc Neil Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,106
+18.35%
|
-
|
|
Dec 22
2021
|
J Michael Carmena Principal Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,549
+13.83%
|
-
|
|
Dec 16
2021
|
Shawn M. Bowman |
SELL
Payment of exercise price or tax liability
|
Direct |
597
-0.97%
|
$25,671
$43.13 P/Share
|
|
Dec 16
2021
|
Michael D. Mc Neil Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,168
-3.35%
|
$49,056
$42.29 P/Share
|
|
Dec 16
2021
|
Zachary B. Fleming Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
762
-1.45%
|
$32,004
$42.29 P/Share
|
|
Dec 16
2021
|
J Michael Carmena Principal Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,748
-2.91%
|
$73,416
$42.29 P/Share
|
|
Oct 26
2021
|
Zachary B. Fleming Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-5.35%
|
$34,000
$34.04 P/Share
|
|
Oct 20
2021
|
Shawn M. Bowman |
SELL
Open market or private sale
|
Direct |
1,000
-3.04%
|
$33,000
$33.99 P/Share
|
|
Oct 05
2021
|
Zachary B. Fleming Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-2.57%
|
$33,000
$33.08 P/Share
|
|
Sep 28
2021
|
Shawn M. Bowman |
SELL
Open market or private sale
|
Direct |
1,000
-5.66%
|
$33,000
$33.33 P/Share
|
|
Aug 24
2021
|
Rebecca E Mc Mahon President - R&D |
BUY
Grant, award, or other acquisition
|
Direct |
5,339
+50.0%
|
-
|
|
Dec 31
2020
|
J Michael Carmena Principal Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
546
+2.62%
|
$5,460
$10.53 P/Share
|
|
Sep 30
2020
|
Michael D. Mc Neil Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,247
+9.5%
|
-
|
|
Sep 30
2020
|
Zachary B. Fleming Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,603
+7.52%
|
-
|
|
Sep 30
2020
|
Shawn M. Bowman |
BUY
Grant, award, or other acquisition
|
Direct |
1,603
+7.91%
|
-
|
|
Sep 30
2020
|
J Michael Carmena Principal Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,517
+6.16%
|
$12,585
$5.27 P/Share
|